Last reviewed · How we verify
XCEL-M-ALPHA and standard rehabilitation
At a glance
| Generic name | XCEL-M-ALPHA and standard rehabilitation |
|---|---|
| Also known as | XCEL-M-ALPHA |
| Sponsor | Banc de Sang i Teixits |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Mesenchymal Stromal Cells for Degenerative Meniscus Injury (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: